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Abstract
Background
Prolyl carboxypeptidase (PRCP) is involved in the regulation of body weight, likely by hydro-
lysing alpha-melanocyte-stimulating hormone and apelin in the hypothalamus and in the
periphery. A link between PRCP protein concentrations in plasma and metabolic disorders
has been reported. In this study, we investigated the distribution of circulating PRCP activity
and assessed its relation with body weight and adipose tissue in obese patients and patients
who significantly lost weight.
Methods
PRCP activity was measured using reversed-phase high-performance liquid chromatogra-
phy in different isolated blood fractions and primary human cells to investigate the distribu-
tion of circulating PRCP. PRCP activity was measured in serum of individuals (n = 75)
categorized based on their body mass index (BMI < 25.0; 25.0–29.9; 30.0–39.9;  40.0 kg/
m2) and the diagnosis of metabolic syndrome. Differences in serum PRCP activity were
determined before and six months after weight loss, either by diet (n = 45) or by bariatric sur-
gery (n = 24). Potential correlations between serum PRCP activity and several metabolic
and biochemical parameters were assessed. Additionally, plasma PRCP concentrations
were quantified using a sensitive ELISA in the bariatric surgery group.
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Results
White blood cells and plasma contributed the most to circulating PRCP activity. Serum
PRCP activity in lean subjects was 0.83 ± 0.04 U/L and increased significantly with a rising
BMI (p<0.001) and decreased upon weight loss (diet, p<0.05; bariatric surgery, p<0.001).
The serum PRCP activity alteration reflected body weight changes and was found to be pos-
itively correlated with several metabolic parameters, including: total, abdominal and visceral
adipose tissue. Plasma PRCP concentration was found to be significantly correlated to
serum PRCP activity (0.865; p<0.001). Additionally, a significant decrease (p<0.001) in
plasma PRCP protein concentration (mean ± SD) before (18.2 ± 3.7 ng/mL) and 6 months
after bariatric surgery (15.7 ± 2.7 ng/mL) was found.
Conclusion
Our novel findings demonstrate that white blood cells and plasma contributed the most to
circulating PRCP activity. Additionally, we have shown that there were significant correla-
tions between serum PRCP activity and various metabolic parameters, and that plasma
PRCP concentration was significantly correlated to serum PRCP activity. These novel find-
ings on PRCP activity in serum support further investigation of its in vivo role and involve-
ment in several metabolic diseases.
Introduction
Prolyl carboxypeptidase (PRCP, EC 3.4.16.2), a lysosomal carboxypeptidase, changes the bio-
logical activity of α-melanocyte-stimulating hormone (α-MSH) [1], as well as angiotensin II
and III [2] and des-Arg9-bradykinin [3] by cleaving off one C-terminal amino acid when ala-
nine or proline are in the penultimate position [4]. Previous reports have suggested an impor-
tant role for PRCP in the regulation of food intake and body weight by truncation of α-MSH
[1]. This 13 amino-acid peptide (referred to as α-MSH 1–13) is a critical anorexigenic neuro-
modulator in the hypothalamus that suppresses appetite and inhibits food intake by binding
target neurons expressing the melanocortin receptors 3 (MC3R) and 4 (MC4R) [5]. Little was
known about the inactivation of α-MSH 1–13, until Wallingford et al. discovered that PRCP is
responsible for removing the C-terminal Val of α-MSH 1–13, producing α-MSH 1–12, which
does not trigger the MCR and thus is not neuroactive [1].
Furthermore, PRCP knockout (KO) mice are known to have a significantly lower body
weight, total fat, BMI and body length, compared to wild-type mice. PRCP KOmice consume
significantly less food compared to controls and have been shown to be resistant to diet-
induced obesity [1]. Pharmacological inhibition of PRCP, centrally as well as solely in the
periphery, decreases food intake in wild-type and obese mice [6,7]. In addition, our group has
shown that pyroglutamated apelin-13, an adipokine mostly known for its cardiovascular
effects, is also truncated by PRCP at the C-terminus [8]. This peptide has been related to obe-
sity and might also play an important role in PRCP’s function in body weight control [9–11].
PRCP is ubiquitously expressed but data concerning the cellular sources of plasma PRCP or
PRCP in different circulating and vascular cell types are scarce [12,13]. Previous reports have
indicated the presence of PRCP in the lysosomes and in the granular fraction of leukocytes
[14,15]. PRCP activity has also been demonstrated in primary human fibroblasts and endothe-
lial cells cultured from human pulmonary arteries [16]. In 1995, Jackman et al. provided
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evidence that PRCP is active in human alveolar macrophages [17]. More recently, PRCP was
purified from human neutrophils, thereby revealing that these cells highly express PRCP [18].
Furthermore, it has been shown that PRCP is not only located in the lysosomes but also on the
cell membrane of endothelial cells [19]. Although these data are informative, these do not per-
mit us to predict which cell or tissue type(s) most likely contribute(s) to the circulating PRCP
activity.
Plasma PRCP concentrations have been shown to be increased in obesity, diabetes, and car-
diovascular dysfunction and significant correlations with several metabolic and cardiovascular
parameters have been determined [18]. More recently, differences in PRCP expression and
function have been observed in the heart, kidney and plasma of Zucker diabetic fatty rats fed a
high-fat diet compared to Zucker lean controls. Plasma PRCP concentrations have been found
to be higher in diabetic rats compared to the controls. Furthermore, PRCP protein has been
found to be significantly elevated in plasma of five uncontrolled diabetic patients and treat-
ment of these patients with anti-diabetic drugs (such as metformin) returned the PRCP pro-
tein levels almost back to baseline. However, the underlying mechanisms by which the
elevated plasma levels were reversed have not been fully elucidated and require further investi-
gation. It is possible that the decrease in PRCP protein levels is related to simultaneous body
weight reduction caused by metformin therapy [20].
Despite information on gene and protein expression, the question regarding the actual
PRCP activity in plasma remains unanswered. Indeed, the majority of PRCP’s functions have
been assigned to its enzymatic activity and to its role in peptide turnover. These PRCP activity
measurements have never been performed in well-characterized larger populations and could
provide complementary information regarding PRCP’s in vivo function.
The aims of this study were 1) to investigate PRCP activity in different primary cell types
(monocytes, macrophages, lymphocytes, granulocytes, endothelial cells) to determine the dis-
tribution of PRCP activity in the circulation and 2) to measure PRCP activity in serum col-
lected from individuals categorized based on their BMI and the diagnosis of metabolic
syndrome (MS). Additionally, differences in serum PRCP activity were determined before and
after significant weight loss, either by diet or by bariatric surgery. Correlations between the
serum PRCP activity and several metabolic and biochemical parameters were assessed. In
addition, plasma PRCP protein concentrations were also quantified in the bariatric surgery
group.
Materials and methods
PRCP activity in human circulation
The study was approved by the local Ethics Committee at the University Clinic of Aachen,
Germany (EK191/14) and blood was collected with written consent of the blood donors.
Human blood was collected from six healthy volunteers using citrate as an anticoagulant and
the first 3 mL was discarded. White blood cells, blood platelets, platelet-rich and platelet-free
plasma were isolated for analysis of PRCP activity.
The number of white blood cells and platelets per mL were counted using an automated
hematology analyser. After adding prostacyclin (100 ng/mL), the blood sample was centri-
fuged for 15 min at 365 g without brakes. The cell pellet was used for the isolation of white
blood cells, as described below. The supernatant, being platelet-rich plasma, was collected, sup-
plemented with acid-citrate-dextrose (ACD) (1:6 Vol.-%) and apyrase (0.1 units/mL), and cen-
trifuged for 10 min at 1045 g without brakes. The supernatant was used to prepare platelet-free
plasma by centrifuging again for 10 min at 2500 g. Instead, the platelet-containing pellet was
gently resuspended in Hepes pH 6.6 containing glucose (1 mg/mL), bovine serum albumin
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(BSA, 1 mg/mL), ACD (1:15 Vol.-%), apyrase (0.1 units/mL) and prostacyclin (100 ng/mL).
After centrifugation for 10 min at 1045 g without brakes, the platelet pellet was gently resus-
pended in Hepes pH 7.45 containing glucose (1 mg/mL) and BSA (1 mg/mL). Isolated cells
were counted using a Neubauer chamber. All fractions were frozen at -20 ˚C for analysis of
PRCP activity.
Where indicated, isolated platelets were stimulated with thrombin (20 units/mL) in the
presence of CaCl2 (2 mM) for 45 min at 37 ˚C. Control platelets were kept for 45 min at 37 ˚C
in the presence of prostacyclin (100 ng/mL). After stimulation, platelets were centrifuged for 2
min at 3000 g without brakes. The supernatants as well as the platelet pellets were frozen at
-20 ˚C for analysis of PRCP activity.
To isolate white blood cells, citrate-anticoagulated human blood was centrifuged for 15 min
at 365 g. The cell pellet was incubated in red blood cell lysis buffer (0.155 M NH4Cl, 0.01 M
KHCO3 and 0.1 mM EDTA in water) for 10 minutes at room temperature. After centrifuga-
tion for 5 min at 300 g, the cells were washed with phosphate buffered saline (PBS), counted
and the cell pellet was frozen at -20 ˚C for PRCP analysis.
To calculate the relative contribution of white blood cells, platelets and platelet-free plasma
to the total PRCP activity in blood, PRCP activity of white blood cell lysates, platelet lysates,
platelet-free plasma as well as total blood lysates were first expressed in U/mL blood, after
which the relative contribution was calculated. For white blood cells and platelets, PRCP activ-
ity in U/mL blood was calculated as U/cell number multiplied by the cell number per mL of
blood. The platelet-free plasma volume fraction of total blood was calculated as “1—haemato-
crit value/100”, neglecting the volume of white blood cells. Next, the contribution of platelet-
free plasma to total circulating PRCP activity (in U/mL blood) was calculated as “PRCP activity
(U/mL plasma) x platelet-free plasma volume fraction of blood”.
PRCP activity in peripheral blood mono- and polymorphonuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient
centrifugation of buffy coats (Blood Transfusion Centre) [21]. Buffy coats were diluted twice in
DPBS (1:1, vol/vol) (Lonza, Verviers, Belgium) and layered on top of the Ficoll-Paque PRE-
MIUM (Sigma-Aldrich, Diegem, Belgium) solution and centrifuged for 40 min at 400 g (no
brakes). PBMCs were collected from the interface and subsequently washed two times with
complete RPMI 1640 medium (Life Technologies, Ledeberg, Belgium). PBMCs of one buffy
coat were grown overnight in complete RPMI 1640 medium in four T25 culture flasks at 37 ˚C
under 5% CO2. On day 2, the non-adherent cells (predominantly lymphocytes) were collected.
The adherent cells (mostly monocytes) were either harvested and collected or differentiated
into M1 and M2 macrophages for 6 days in complete RPMI medium supplemented with 100
ng/mL granulocyte macrophage colony stimulating factor (Immunotools, Friesoythe, Ger-
many) or 20 ng/mL macrophage colony stimulating factor (Immunotools) according to our in-
house protocol [22]. Macrophages were harvested or further activated by incubation of the cells
with 20 ng/mL lipopolysaccharide (LPS, Sigma-Aldrich) and 100 U/mL interferon-γ (IFN-γ,
Immunotools) for 24 h for M1 activation and with 20 ng/mL interleukin-4 (Immunotools) for
M2 activation. To confirm appropriate macrophage activation by these stimulation protocols,
we determined tumor necrosis factor-α (TNFα) levels in the 8 h aspirate and interleukin-6 (IL-
6), interleukin-1β (IL-1β) and interleukin-10 (IL-10) levels in the 24 h aspirate by using ELISA.
All ELISA’s were performed according to the manufacturer’s instructions (Immunotools) [22].
Subsets of lymphocytes (CD4+ T cells, CD8+ T cells and CD19+ B cells) were isolated from
PBMCs using Dynabeads FlowComp™Human CD4, CD8 and CD19 pan B (Life Technolo-
gies), according to manufacturer’s instructions.
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Granulocytes were isolated from the lower fraction of the Ficoll-Paque centrifugation. A
6% dextran (Sigma-Aldrich) sedimentation and red blood cell lysis was performed to obtain a
pure granulocyte population. According to Maqbool et al.> 95% of the isolated cells are
neutrophils [23]. For confirmation, hematoxylin and eosin staining was performed. Next,
granulocytes were activated by incubating the cells for 30 min with 10 μM phorbol 12-myris-
tate 13-acetate (PMA, Sigma-Aldrich) at 37 ˚C under 5% CO2. Supernatants were collected
where relevant and all cells described above were lysed for PRCP activity measurement (S1
Appendix).
Human aortic endothelial and smooth muscle cells
Human aortic endothelial (EC) cells and human aortic smooth muscle (SMC) cells (both from
Promocell, Heidelberg, Germany) were cultured in Endothelial Cell culture MediumMV,
respectively, Smooth Muscle Cell growth medium 2 (Promocell) according to the manufactur-
er’s protocol. Cells were plated in 6 well plates and stimulated with 10 ng/mL TNFα for 24 h.
Supernatants were collected and the cells were lysed for PRCP activity measurements.
Cell lysates
Washed cells were suspended in a lysis buffer for PRCP activity (1% octylglucoside, 10 mM
EDTA, 70 μg/mL aprotinin in a 50 mM Tris buffer, pH 8.3). Suspensions were then incubated
on ice for 1 h at 4 ˚C and centrifuged for 10 min at 12000 g at 4 ˚C. The supernatant was with-
held and stored at -20 ˚C until further analysis. The protein content of the cell lysates was
determined according to the Bradford method using bovine serum albumin (Sigma-Aldrich)
as a standard [24].
PRCP activity and protein measurements
PRCP activity was measured using a previously validated reversed-phase high-performance
liquid chromatography assay [25]. The hydrolysis of the substrate N-benzyloxycarbonyl-
L-Pro-Phe (Z-Pro-Phe, Bachem, Bubendorf, Switzerland) by PRCP at 37 ˚C leads to the release
of Z-Pro and Phe. The quantification of the peak height of either of these two products is pro-
portional to the PRCP activity, which is expressed as units per liter (U/L). One unit defines the
amount of enzyme needed to hydrolyse 1 μmol of substrate per minute. A sensitive in-house
polyclonal antibody-based ELISA was used for the measurement of PRCP protein concentra-
tions in plasma [18].
Study populations
Patients visiting the obesity clinic of the Antwerp University Hospital (a tertiary referral facil-
ity) for a problem of overweight or obesity, presenting at their own initiative or referred by
their treating physician, were consecutively recruited. Every patient underwent a standard
metabolic work-up approved by the Ethics Committee of the Antwerp University Hospital
(reference 6/25/125, Belgian registration number B30020071389) and requiring written
informed consent of the patient. All patients were female and predominantly of Western Euro-
pean descent. At enrolment none were involved in a weight management program. Subjects
had to be 18 years or older. PRCP activity was first measured in baseline serum of female adults
categorized based on their BMI (< 25.0; 25.0–29.9; 30.0–39.9;  40.0 kg/m2) and the diagnosis
of metabolic syndrome according to Alberti et al [26]. 10–15 patients were included per group
(study cohort 1). Serum PRCP activity was also investigated in female adults before and 6
months after weight loss either by diet (n = 45) or by bariatric surgery (n = 24) (study cohort
Serum prolyl carboxypeptidase activity in lean and obese subjects
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2). Population characteristics are summarized in Tables 1 and 2. In addition, serum PRCP
activity was correlated with several metabolic and biochemical parameters and with plasma
PRCP protein concentration. See S2 Appendix for individual data points and more informa-
tion about the inclusion criteria of the patients and metabolic work-up.
Statistical analysis
Data were analysed using the statistical SPSS software version 22 (IBM, New York, United
States). Differences in PRCP activity between the various blood fractions collected from six
healthy volunteers were analysed with Friedman andWilcoxon Signed-Rank test. Differences
in PRCP activity between various cell types and differences in cytokine levels in the superna-
tant of monocytes and (activated) M1 macrophages were analysed with Kruskal-Wallis and
Mann-Whitney U-tests. P-values were corrected for multiple testing based on scientifically rel-
evant pairwise comparisons. A one-way ANOVA, followed by a post-hoc analysis, using
Tukey’s HSD correction for multiple comparisons, was carried out to assess differences in
serum PRCP activity between the different BMI categories. An ANCOVA was used to assess
the influence of both BMI and metabolic syndrome on the PRCP activity in serum. A t-test for
paired samples was used to compare the PRCP activity and protein concentration before and
after weight loss either by diet or bariatric surgery. The relation between the PRCP activity and
several metabolic and biochemical parameters and PRCP protein concentration was described
using Pearson’s correlation coefficient. Both baseline levels as well as changes after weight loss
(indicated by Δdelta) were investigated. PRCP activity levels are presented as boxplots or as
median with interquartile range (GraphPad Prism 7 software, La Jolla, California, USA). Sig-
nificant changes are indicated with an asterisk (⇤p<0.05, ⇤⇤p<0.01, ⇤⇤⇤p<0.001).
Table 1. Patient characteristics of study cohort 1.
BMI< 25 BMI 25–29.9 BMI 30–39.9 BMI  40
MS- MS- MS+ MS- MS+ MS- MS-
N 15 10 10 10 10 10 10
Age (years) 37.3 ± 9.9 41.0 ± 17.4 44.1 ± 11.8 43.4 ± 11.0 42.3 ± 15.2 35.8 ± 12.4 43.4 ± 16.5
Height (m) 1.66 ± 0.06 1.66 ± 0.08 1.65 ± 0.05 1.66 ± 0.03 1.68 ± 0.1 1.67 ± 0.06 1.62 ± 0.05
Weight (kg) 59.0 ± 4.9 76.7 ± 8.3 78.2 ± 4.3 95.1 ± 8.1 99.4 ± 14.9 120.3 ± 12.7 119.3 ± 11.9
BMI (kg/m2) 21.4 ± 1.5 27.7 ± 1.1 28.3 ± 1.3 34.7 ± 2.9 35.1 ± 1.8 43.3 ± 3.2 45.5 ± 3.5
Mean value ± SD is shown for all parameters, except N (absolute number). MS-/+: diagnosis of the metabolic syndrome no (-), yes (+)
https://doi.org/10.1371/journal.pone.0197603.t001
Table 2. Patient characteristics of study cohort 2.
Bariatric surgery Diet
Before After Before After
N 24 45
Age (years) 38.7 ± 12.6 46.0 ± 12.8
Height (m) 1.64 ± 0.05 1.65 ± 0.06
Weight (kg) 114.6 ± 17.6 88.1 ± 15.2 96.2 ± 16.5 86.2 ± 16.2
BMI (kg/m2) 42.5 ± 6.1 32.7 ± 5.3 35.3 ± 4.9 31.6 ± 4.8
Mean value ± SD is shown for all parameters, except N (absolute number).
https://doi.org/10.1371/journal.pone.0197603.t002
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Results
PRCP activity in human circulation
PRCP activity (median with interquartile range) was measured in total lysed blood (12.3
[10.5–13.5] mU/g), platelet-rich (10.3 [9.1–11.4] mU/g) and platelet-free (9.8 [8.9–11.1] mU/
g) plasma of 6 healthy donors. As shown in Fig 1A, no significant differences were observed
between these groups, indicating that there is little to no PRCP activity found in platelets
(p = 0.174). PRCP was also measured in isolated white blood cells, resting platelets and plate-
lets activated with thrombin. Again, low PRCP activity was found in resting platelets and
thrombin activation had no effect on the enzyme activity. The specific activity measured in
white blood cells was approximately fifty times higher compared to platelets (p = 0.028, Fig
1B). When comparing the relative contribution of blood fractions to the circulating PRCP
activity, white blood cells and the platelet-free plasma fraction contributed for 41%, respec-
tively, 46% to the total PRCP activity in blood (Fig 1C). Overall, white blood cells and the
plasma fraction contribute most to the circulating PRCP activity.
PRCP activity in primary human cells
Appropriate activation of M1 macrophages was confirmed by ELISA, since the levels of TNFα,
IL-1β and IL-6 were significantly upregulated in the supernatant of activated M1 macrophages
(p<0.05, data not shown). PRCP activity is significantly higher in resting M1 macrophages
(p = 0.003) compared to monocytes. Even when we take into account that freshly isolated
monocytes would be a more suitable comparator as the adhesion to plastic and overnight cul-
ture could already alter the monocyte phenotype, these results clearly show that an increase in
PRCP activity was found upon monocyte-to-M1-macrophage differentiation. M2 macrophage
activation could not be confirmed, since no clear upregulation of IL-10 could be measured in
the supernatant of activated M2 macrophages. Therefore, no conclusions could be drawn con-
cerning the M2 macrophages. Furthermore, a decrease in PRCP activity was observed after
PMA stimulation of granulocytes (p = 0.007). The PRCP activity is higher in CD8+ cytotoxic T
cells compared to CD4+ helper T cells. Human aortic endothelial and smooth muscle cells
were stimulated with TNFα for 24 h. However, no significant difference in PRCP activity was
found after stimulation. The PRCP activity in human aortic smooth muscle cells is higher than
in the human aortic endothelial cells. The results are all shown in Fig 2. In addition to human
cells, we also isolated and cultured primary cells from the bone marrow of wild-type mice.
Similar results as for the human blood cell populations were found (S3 Appendix).
Fig 1. PRCP activity in human circulation. (A) PRCP activity was measured in total lysed blood, platelet-rich and
platelet-free plasma but no significant changes were found (p = 0.174). (B) PRCP activity was significantly higher in
lysed white blood cells compared to resting and thrombin-activated blood platelets (p = 0.028). (C) PRCP activity
measured in human blood is mainly attributed to white blood cells and the plasma fraction. (⇤p<0.05, n = 4–6 per
group).
https://doi.org/10.1371/journal.pone.0197603.g001
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Serum PRCP activity in obese patients
PRCP activity was measured in serum of 15 lean and 60 obese female patients, which were fur-
ther divided into three subgroups based on their BMI. The mean serum PRCP activity
(mean ± SD) in lean subjects (BMI< 25.0 kg/m2) was 0.83 ± 0.04 U/L, 1.03 ± 0.04 U/L in over-
weight patients (BMI 25.0–29.9 kg/m2), 1.13 ± 0.03 U/L in obese patients (BMI 30.0–39.9 kg/
m2) and 1.23 ± 0.05 U/L in morbidly obese patients (BMI  40.0 kg/m2). Thus, the PRCP
activity in serum of the groups with elevated BMI is significantly elevated compared to the
PRCP activity in the lean group, as shown in Fig 3A. The three subgroups were then further
divided based on the diagnosis of metabolic syndrome (MS- or MS+). As presented in Fig 3B,
no significant differences in mean serum PRCP activity were found between metabolic syn-
drome (MS+) patients and those without (MS-) (p> 0.05). In parallel, we studied PRCP activ-
ity in serum of rats with metabolic syndrome. Again, no significant differences in serum PRCP
activity between the controls and rats with metabolic syndrome were found (S4 Appendix).
Correlations between serum PRCP activity in overweight/obese patients (n = 60) and patient
age, several metabolic and biochemical parameters were investigated. An overview of the sig-
nificant correlations is given in Table 3 and correlations between serum PRCP activity and
BMI, body weight and total abdominal tissue are shown in Fig 4. The correlation with the
Fig 2. PRCP activity in primary human cells. (A) PRCP activity was significantly increased upon monocyte-to-
macrophage (M1 phenotype) differentiation. (B) PRCP activity was measured in different subsets of lymphocytes and
was found highest in CD8+ cytotoxic T cells. (C) PRCP activity was measured in resting and PMA-activated
granulocytes and (D) in control and stimulated (TNFα, 24h) human aortic endothelial and smooth muscle cells.
(⇤⇤p<0.01, n = 3–11 per group).
https://doi.org/10.1371/journal.pone.0197603.g002
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amount of adipose tissue is intriguing since this suggests that PRCP might be secreted in
serum by adipocytes. No correlations were found with systolic and diastolic blood pressure,
lipid parameters, percentage glycated haemoglobin A1, oral glucose tolerance test results
(baseline glucose and insulin levels and glucose level at 120 min) and high-sensitive C-reactive
protein levels (r< 0.25).
Serum PRCP activity before and after weight loss
A group of 69 obese patients were treated with either a hypocaloric diet (n = 45) or bariatric
surgery (n = 24). Diet as well as bariatric surgery caused a significant decrease in body weight
Fig 3. Serum PRCP activity in lean and obese patients. (A) PRCP activity was measured in serum of lean and obese
patients categorized based on their BMI and (B) the diagnosis of metabolic syndrome (no (-), yes (+)). (⇤⇤⇤p<0.001,
n = 10–20 per group).
https://doi.org/10.1371/journal.pone.0197603.g003
Table 3. Significant correlations between serum PRCP activity in overweight/obese patients (n = 60) and several
metabolic parameters.
Parameter Pearson correlation p-value
Body weight (kg) 0.409 0.001
BMI (kg/m2) 0.392 0.002
Waist (cm) 0.385 0.002
Hip (cm) 0.360 0.005
Visceral fat (cm2) 0.376 0.003
Subcutaneous fat (cm2) 0.352 0.006
Total abdominal fat (cm2) 0.404 0.001
https://doi.org/10.1371/journal.pone.0197603.t003
Fig 4. Correlations between serum PRCP activity and BMI, body weight and total abdominal adipose tissue.
Correlation between serum PRCP activity and (A) BMI (p = 0.002), (B) body weight (p = 0.001) and (C) total
abdominal adipose tissue (p = 0.001) in overweight/obese patients (n = 60).
https://doi.org/10.1371/journal.pone.0197603.g004
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(mean ± SD; 10.0 ± 7.2 vs. 26.5 ± 7.9 kg, p< 0.001) and BMI (mean ± SD; 3.6 ± 2.7 vs.
9.8 ± 3.0 kg/m2, p< 0.001) although more pronounced after surgery. The mean serum PRCP
activity (mean ± SD) before and 6 months after diet was 0.99 ± 0.25 U/L and 0.90 ± 0.25 U/L,
while before and after bariatric surgery 1.09 ± 0.24 U/L and 0.90 ± 0.19 U/L. In both cases
there was a significant decrease in the mean serum PRCP activity (mean ± SD; 0.08 ± 0.03 U/L
for diet and 0.19 ± 0.03 U/L for bariatric surgery). Line plots indicating the individual change
in serum PRCP activity after diet or bariatric surgery are shown in Fig 5. Serum PRCP activity
correlated significantly with plasma PRCP protein concentration (0.865; p<0.001) (Fig 6). The
mean plasma PRCP protein concentrations (mean ± SD) before and 6 months after bariatric
surgery were 18.2 ± 3.7 ng/mL and 15.7 ± 2.7 ng/mL. We also found a significant decrease
(p<0.001) in the mean plasma PRCP protein concentration (mean ± SD; 2.43 ± 2.26 ng/mL)
upon weight loss.
Fig 5. Serum PRCP activity changes after weight loss. Line plots indicating the individual change in PRCP activity in
serum of patients who lost weight either by diet (n = 45, p = 0.015) or by bariatric surgery (n = 24, p< 0.001).
https://doi.org/10.1371/journal.pone.0197603.g005
Fig 6. Correlation between serum PRCP activity and plasma PRCP protein concentration. Correlation between
serum PRCP activity and plasma PRCP protein concentration in the bariatric surgery group (0.865; p< 0.001, n = 24).
https://doi.org/10.1371/journal.pone.0197603.g006
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In the bariatric surgery group significant positive correlations were found between the
decrease in serum PRCP activity and the decrease in body weight, BMI, total abdominal adi-
pose tissue, visceral abdominal adipose tissue and subcutaneous abdominal adipose tissue. An
inverse correlation was found with the increase in high-density lipoprotein cholesterol. Addi-
tional positive correlations with the decrease in waist and hip circumference, total cholesterol,
low-density lipoprotein cholesterol and baseline glucose level were found in the diet group.
These results are all summarized in Table 4.
Discussion
The presence of PRCP protein and activity in the circulation has previously been reported,
but the distribution and possible in vivo relevance of circulating PRCP remained unclear
[18,20,25,27].
The first aim of this study was to unravel the distribution of PRCP activity in human circu-
lation. We found that white blood cells and plasma contributed the most to the circulating
PRCP activity. In contrast, very low PRCP activity was found in resting and thrombin-acti-
vated blood platelets. Our next experiments were focused on finding which cells were poten-
tially responsible for the plasma activity and which subsets of white blood cells significantly
expressed PRCP. The highest PRCP activity was measured in aortic smooth muscle cells, fol-
lowed by M1 macrophages, granulocytes, aortic endothelial cells and lymphocytes. A signifi-
cant upregulation of PRCP activity was observed upon monocyte-to-M1-macrophage
differentiation. M1 macrophages are considered to be the pro-inflammatory macrophages,
which might indicate a function for PRCP in the inflammatory response [28,29]. This enzyme
is thought to exert its function in inflammation via activation of the prekallikrein pathway
with subsequent bradykinin formation [3,30,31]. Also, previous reports have already linked
plasma PRCP to C-reactive protein and several inflammatory cytokines [20,27]. However, in
our study populations no significant correlations with serum PRCP activity and C-reactive
protein levels were found. Another explanation for the increased PRCP activity in macro-
phages could be that monocyte-to-macrophage differentiation is associated with an increase in
cytoplasmic volume and more specifically with the development of larger lysosomal and mito-
chondrial structures to enhance their degradative capacity [32–34]. Activation of M1 macro-
phages through the classical LPS/IFN-γ pathway leads to a decrease in PRCP activity,
indicating that PRCP could potentially be secreted. However, PRCP activity levels were
Table 4. Correlations between the decrease in PRCP activity and changes in several metabolic and biochemical parameters after diet or bariatric surgery (⇤p 0.05,
⇤⇤p 0.01).
Parameter Bariatric surgery Diet
Pearson correlation p-value Pearson correlation p-value
ΔBody weight (kg) 0.472 0.020⇤ 0.389 0.008⇤⇤
ΔBMI (kg/m2) 0.405 0.050⇤ 0.385 0.009⇤⇤
ΔWaist (cm) 0.293 0.164 0.332 0.026⇤
ΔHip (cm) 0.230 0.280 0.402 0.006⇤⇤
ΔVisceral fat (cm2) 0.472 0.020⇤ 0.383 0.010⇤⇤
ΔSubcutaneous fat (cm2) 0.253 0.232 0.326 0.031⇤
ΔTotal abdominal fat (cm2) 0.414 0.044⇤ 0.381 0.011⇤
ΔTotal cholesterol (mg/dL) -0.148 0.490 0.420 0.004⇤⇤
ΔHDL cholesterol (mg/dL) -0.498 0.013⇤ 0.174 0.253
ΔLDL cholesterol (mg/dL) -0.116 0.606 0.377 0.011⇤
ΔFasting glucose (mg/dL) 0.361 0.083 0.314 0.035⇤
https://doi.org/10.1371/journal.pone.0197603.t004
Serum prolyl carboxypeptidase activity in lean and obese subjects
PLOS ONE | https://doi.org/10.1371/journal.pone.0197603 May 17, 2018 11 / 15
undetectable in the cell culture medium. A more pronounced decrease in PRCP activity was
found after degranulation of granulocytes caused by PMA-stimulation. Once more, these
results point to a granular localisation of PRCP and a possible function in the immune
response [18]. The highest PRCP activity was found in cytotoxic T cells compared to helper T
cells and B cells. Furthermore, PRCP activity remained unchanged after TNFα stimulation of
human aortic endothelial and smooth muscle cells [35–36].
The development of a sensitive immunoassay by Xu et al. has demonstrated that plasma
protein concentrations of PRCP are increased in obese patients and are even more elevated in
patients with both obesity and diabetes. Strong correlations with metabolic (BMI, blood glu-
cose, etc.) parameters have been reported [18]. Complementary to this study, we investigated
PRCP activity in the serum of normal, overweight, obese and morbidly obese patients. We
found that serum PRCP activity was increased with a rising BMI the PRCP activity in serum of
the groups with elevated BMI is significantly elevated compared to the PRCP activity in the
lean group. In addition to correlations with BMI, body weight, waist and hip circumference,
we also found strong associations with the amount of total, visceral and subcutaneous abdomi-
nal adipose tissue. The ratio of PRCP protein concentration to activity in serum could reflect
the severity of obesity and sheds some much needed light on the possible additional source(s)
of circulating PRCP. Moreover, this could potentially aid in the determination of PRCP’s
potential role in regulating levels of intact apelin and α-MSH, two peptides involved in the reg-
ulation of food intake.
Since polymorphisms of the PRCP gene have been related to metabolic syndrome among
coronary artery disease patients [37], we also categorized the patients based on metabolic syn-
drome. However, no significant difference in PRCP activity between the MS- and MS+ groups
were found. Whether the existence of metabolic syndrome affects circulating PRCP activity
specifically in patients with coronary artery disease remains to be investigated and will be
addressed in future studies.
Aside from investigating PRCP activity in overweight and obese patients, we also explored
its profile after weight loss. Thus, PRCP activity was measured in 24 patients who underwent
bariatric surgery and 45 patients who were put on a calorie-restricted diet. PRCP activity and
body weight decreased significantly after diet but even more pronounced after bariatric
surgery, which is also associated with several dietary guidelines and restrictions [38]. Again,
significant correlations were found with parameters concerning weight, waist and hip circum-
ference and the amount of adipose tissue. The role of PRCP in adipocytes deserves further
study, especially because adipocytes produce and secrete apelin-13, a substrate of PRCP. A
strong correlation between the serum PRCP activity and plasma protein concentration was
found, thus confirming the specificity of our activity measurements. Moreover, we confirmed
the influence of weight loss on plasma PRCP protein concentrations. Our results suggested
that both PRCP activity, as well as PRCP protein concentration, can be used to investigate the
regulation of PRCP in plasma.
On the other hand, endothelial dysfunction, as observed in obese patients [39], may also lie
at the basis of the raised PRCP protein concentrations in plasma, since PRCP has been shown
to be located on the membrane of endothelial cells and to regulate endothelial cell growth
[18,40].
Conclusion
Our study was the first comprehensive investigation of the distribution of PRCP activity in
human circulation. We have demonstrated that white blood cells and plasma contribute the
most to circulating PRCP activity. Serum PRCP activity was found to correlate with plasma
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PRCP protein concentration, body weight and the amount of adipose tissue. These findings,
taken together with the recent observation that the adipokine apelin-13 is hydrolysed by
PRCP, underscore the importance of further research needed in this field to fully understand
its regulation and biological function in body weight control. Gaining a greater understanding
of PRCP’s multi-faceted biological functions could open up novel therapeutic avenues for the
treatment of obesity.
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